{"product_id":"lucipona-ponatinib","title":"LuciPona (Ponatinib)","description":"\u003ch2\u003eAbout Ponatinib \u003c\/h2\u003e\u003cp\u003ePonatinib is a medication used for the treatment of chronic myeloid leukemia and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia.  It is a multi-targeted tyrosine-kinase inhibitor.\u003csup id=\"cite_ref-pmid20513156_5-0\" class=\"reference\"\u003e\u003c\/sup\u003e Some forms of chronic myeloid leukemia, those that have the T315I mutation, are resistant to current therapies such as imatinib. Ponatinib has been designed to be effective against these types of tumors.\u003c\/p\u003e\u003ch3\u003eChronic Myeloid Leukemia\u003c\/h3\u003e\u003ch4\u003eChronic phase (CP) chronic myeloid leukemia (CML)\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated for patients with CP-CML with resistance or intolerance to at least 2 prior kinase inhibitors\u003c\/li\u003e\n\u003cli\u003e45 mg PO qDay initially\u003c\/li\u003e\n\u003cli\u003eReduce to 15 mg PO qDay upon achievement of ≤1% BCR-ABL1IS\u003c\/li\u003e\n\u003cli\u003eRe-escalate dose to previously tolerated dosage of 30 mg or 45 mg PO qDay in patients with loss of response\u003c\/li\u003e\n\u003cli\u003eContinue until loss of response at the re-escalated dose or unacceptable toxicity\u003c\/li\u003e\n\u003cli\u003eConsider discontinuing treatment if response has not occurred by 3 months\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eAccelerated phase (AP) or blast phase (BP) CML\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated for AP-CML or BP-CML for whom no other kinase inhibitors are indicated, and for T315I-postive CML (CP, AP, BP)\u003c\/li\u003e\n\u003cli\u003eOptimal dose not identified\u003c\/li\u003e\n\u003cli\u003e45 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eConsider reducing dose for AP-CML in patients who have achieved a major cytogenetic response\u003c\/li\u003e\n\u003cli\u003eContinue until loss of response or unacceptable toxicity\u003c\/li\u003e\n\u003cli\u003eConsider discontinuing treatment if response has not occurred by 3 months\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003ePhiladelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)\u003c\/h3\u003e\u003ch4\u003eNewly diagnosed in combination with chemotherapy\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndication for Ph+ ALL based on minimal residual disease (MRD)-negative complete remission (CR) at end of induction\u003c\/li\u003e\n\u003cli\u003e30 mg PO qDay; reduce to 15 mg PO qDay upon achievement of MRD-negative (≤0.01% BCR::ABL1\/ABL1) CR at end of induction\u003c\/li\u003e\n\u003cli\u003eContinue in combination with chemotherapy for up to 20 cycles (each cycle is 28 days) until loss of response or unacceptable toxicity\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eInduction (cycles 1-3)\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003ePonatinib 30 mg PO qDay, plus\u003c\/li\u003e\n\u003cli\u003eVincristine 1.4 mg\/m\u003csup\u003e2\u003c\/sup\u003e IV on Days 1 and 14 (not to exceed 2 mg\/dose), a\u003cb\u003end\u003c\/b\u003e\n\u003c\/li\u003e\n\u003cli\u003eDexamethasone: 40 mg (age \u0026lt;60 yr) or 20 mg (age ≥60 yr) PO on Days 1-4 and Days 11-14\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eConsolidation (cycles 4-9, alternating methotrexate and cytarabine)\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003ePonatinib 30 mg (or decreased to 15 mg if in MRD-negative CR) PO qDay, plus\u003c\/li\u003e\n\u003cli\u003eMethotrexate (cycles 4, 6, and 8): 1000 mg\/m\u003csup\u003e2\u003c\/sup\u003e (age \u0026lt;60 yr) or 250 mg\/m\u003csup\u003e2\u003c\/sup\u003e (age ≥60 yr) IV on Day 1, OR\u003c\/li\u003e\n\u003cli\u003eCytarabine (cycles 5, 7, and 9): 1000 mg\/m\u003csup\u003e2\u003c\/sup\u003e (age \u0026lt;60 yr) or 250 mg\/m\u003csup\u003e2\u003c\/sup\u003e (age ≥60 yr) IV q12hr on Days 1, 3, and 5\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eMaintenance (cycles 10-20)\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003ePonatinib 30 mg (or decreased to 15 mg if in MRD-negative CR) PO qDay, plus\u003c\/li\u003e\n\u003cli\u003eVincristine 1.4 mg\/m\u003csup\u003e2\u003c\/sup\u003e IV on Day 1 (not to exceed 2 mg\/dose), and\u003c\/li\u003e\n\u003cli\u003ePrednisone: 200 mg (aged \u0026lt;60 yr) or 100 mg (age ≥60 to 69 yr) or 50 mg (age ≥70 yr) PO on Days 1-5\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eMonotherapy\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated for patients with Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-postive Ph+ ALL\u003c\/li\u003e\n\u003cli\u003eOptimal dose not identified\u003c\/li\u003e\n\u003cli\u003e45 mg PO qDay initially\u003c\/li\u003e\n\u003cli\u003eContinue until loss of response or unacceptable toxicity\u003c\/li\u003e\n\u003cli\u003eConsider discontinuing treatment if response has not occurred by 3 months\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954719787,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0866.jpg?v=1787022225","url":"https:\/\/xomeds.com\/products\/lucipona-ponatinib","provider":"XOMEDS","version":"1.0","type":"link"}